Steroids may shorten hospital stay for pneumonia patients

Patients with pneumonia may spend fewer days in the hospital if they are given steroids along with antibiotics and supportive care. That's the finding of a Mayo Clinic analysis of eight randomized-controlled clinical trials involving more than 1,100 patients. The results appear in the March issue of the Journal of Hospital Medicine.

"Given that the average hospital stay for community-acquired pneumonia can range from nine to 23 days, the prospect of speeding recovery, even by a day or two, is helpful," says co-author M. Rizwan Sohail, M.D., a Mayo infectious disease specialist.

Pneumonia is a major health risk, especially in the elderly, the very young and those with chronic lung diseases. Five percent to 15 percent of pneumonia patients die from it, depending on its severity and the treatment administered, recent studies report.

Mayo researchers reviewed eight clinical trials conducted from 2000 to 2011. Most of the research studied patients between 60 and 80. While steroid use didn't prevent deaths, for those who survived the pneumonia, it reduced their hospital stays an average of 1.21 days.

The researchers say that while the findings are significant, the data were not strong enough for them to recommend routine use of steroids for ; more study is needed. They add that continuing any steroids patients may already be taking is reasonable.

The study was led by Majid Shafiq, M.D., a former researcher currently at Johns Hopkins University.

A similar, but unrelated study by A.R. Khan, M.D., involving researchers at Mayo Clinic and other institutions, found that use of certain lipid-lowering medicines, commonly referred to as statins, may have a role in reducing the risk of developing community-acquired pneumonia and associated mortality. That study, published last month in PLOS ONE, reviewed 18 clinical trials. The evidence was considered less reliable due to design issues, bias and other factors in the original studies.

Vaccination remains the most powerful tool in infection prevention, researchers say. The Centers for Disease Control and Prevention recommends that all adults 65 or older should receive the vaccine and that anyone 19 or older with risk factors such as immune deficiency or chronic lung disease also should get it.

add to favorites email to friend print save as pdf

Related Stories

Glucose levels at admission predict death in pneumonia

May 30, 2012

(HealthDay) -- For patients with community-acquired pneumonia without preexisting diabetes, serum glucose levels at admission are predictive of death at 28 and 90 days, according to a study published online ...

Statins associated with lower risk of death from pneumonia

Oct 27, 2008

Individuals who take cholesterol-lowering statins before being hospitalized with pneumonia appear less likely to die within 90 days afterward, according to a report in the October 27 issue of Archives of Internal Medicine, one of ...

Flu vaccine may not protect seniors well

Aug 01, 2008

A Group Health study in the August 2 issue of The Lancet adds fuel to the growing controversy over how well the flu vaccine protects the elderly.

Recommended for you

Liberia holds Senate vote amid Ebola fears

3 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate vote that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

23 hours ago

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

23 hours ago

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

Discovery of genes that predispose a severe form of COPD

Dec 19, 2014

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases (INER), found that the mestizo Mexican population has a number of variations in certain genes that predispose ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.